Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angina
Update on GENASIS trial announced by Corautus Genetics
March 24th, 2006
Corautus Genetics, Inc., (VEGF) announced an update of its GENASIS phase IIb clinical trial that is evaluating the safety and efficacy of VEGF-2 for the treatment of severe angina resulting from cardiovascular disease. Corautus expects to complete the enrollment of 404 patients in its phase IIb GENASIS trial around June 30, 2006. Corautus had previously projected that it would complete enrollment by March 31, 2006. To date, 276 patients have been treated in the trial. "The additional time is primarily attributable to a decrease in the rate of enrollment which began in December and continued through January as well as delays in initiating several...
Source: Drug Week (2006-03-24)
|
